

Huilai Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6490912/publications.pdf>

Version: 2024-02-01

94
papers

2,058
citations

331670

21
h-index

276875

41
g-index

96
all docs

96
docs citations

96
times ranked

2803
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199. | 1.6 | 277 |
| 2 | Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 3026-3034. | 1.4 | 168 |
| 3 | Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69. | 17.0 | 155 |
| 4 | Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2020, 26, 4216-4224. | 7.0 | 126 |
| 5 | Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. <i>Leukemia</i> , 2020, 34, 533-542. | 7.2 | 104 |
| 6 | Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2670-2681. | 1.4 | 77 |
| 7 | MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 1311-1324. | 1.6 | 64 |
| 8 | Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. <i>Oncotarget</i> , 2016, 7, 33350-33362. | 1.8 | 56 |
| 9 | A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors. <i>BioMed Research International</i> , 2015, 2015, 1-7. | 1.9 | 53 |
| 10 | miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. <i>Protein and Cell</i> , 2016, 7, 899-912. | 11.0 | 45 |
| 11 | Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. <i>Blood</i> , 2022, 139, 3148-3158. | 1.4 | 43 |
| 12 | Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12. | 17.0 | 40 |
| 13 | Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer. <i>Journal of Nanobiotechnology</i> , 2021, 19, 181. | 9.1 | 40 |
| 14 | TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance. <i>Materials Science and Engineering C</i> , 2018, 84, 108-117. | 7.3 | 38 |
| 15 | Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 217. | 2.8 | 36 |
| 16 | Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-9. | 1.1 | 34 |
| 17 | Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. <i>Leukemia Research</i> , 2017, 56, 29-35. | 0.8 | 30 |
| 18 | Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2107-2121. | 6.7 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126. | 2.9 | 30 |
| 20 | Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas. <i>Journal of Experimental Medicine</i> , 2021, 218, . | 8.5 | 29 |
| 21 | Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. <i>European Journal of Cancer</i> , 2022, 164, 117-126. | 2.8 | 27 |
| 22 | Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018, 109, 3943-3952. | 3.9 | 26 |
| 23 | Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. <i>Haematologica</i> , 2017, 102, 755-764. | 3.5 | 24 |
| 24 | Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome. <i>International Journal of Cancer</i> , 2019, 145, 1414-1422. | 5.1 | 24 |
| 25 | Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1147-1156. | 7.0 | 23 |
| 26 | CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 360-367. | 1.7 | 21 |
| 27 | Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2019, 134, 755-755. | 1.4 | 21 |
| 28 | Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 167. | 17.0 | 21 |
| 29 | Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 1629-1636. | 5.2 | 20 |
| 30 | Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. <i>Hematological Oncology</i> , 2019, 37, 270-276. | 1.7 | 18 |
| 31 | Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. <i>Journal of Cancer</i> , 2020, 11, 7001-7008. | 2.5 | 17 |
| 32 | Upconverting and persistent luminescent nanocarriers for accurately imaging-guided photothermal therapy. <i>Materials Science and Engineering C</i> , 2017, 79, 191-198. | 7.3 | 16 |
| 33 | Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. <i>Journal of Hematology and Oncology</i> , 2022, 10, e004114. | | 16 |
| 34 | The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study. <i>Cancer Biology and Medicine</i> , 2021, 18, 841-848. | 3.0 | 15 |
| 35 | Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase III trial. <i>American Journal of Hematology</i> , 2022, 97, 623-629. | 4.1 | 15 |
| 36 | Combined Analysis of CHIP Sequencing and Gene Expression Dataset in Breast Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 361-368. | 1.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e381-e389. | 0.4 | 14 |
| 38 | Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <i>Targeted Oncology</i> , 2019, 14, 149-158. | 3.6 | 14 |
| 39 | Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2020, 136, 1-1. | 1.4 | 13 |
| 40 | Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes. <i>Frontiers in Oncology</i> , 2022, 12, 813100. | 2.8 | 13 |
| 41 | Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 73-89. | 6.7 | 13 |
| 42 | Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9. | 2.2 | 12 |
| 43 | A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323. | 2.8 | 12 |
| 44 | Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma. <i>Oncology Letters</i> , 2019, 18, 1415-1423. | 1.8 | 11 |
| 45 | Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer. <i>Oncology Letters</i> , 2016, 12, 3882-3888. | 1.8 | 10 |
| 46 | Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 616-626. | 2.2 | 10 |
| 47 | Integrated analysis of genome-wide gene expression and DNA methylation microarray of diffuse large B-cell lymphoma with TET mutations. <i>Molecular Medicine Reports</i> , 2017, 16, 3777-3782. | 2.4 | 9 |
| 48 | Electrocardiographic characteristics of diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy. <i>Journal of Electrocardiology</i> , 2020, 60, 195-199. | 0.9 | 9 |
| 49 | AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 445-445. | 1.4 | 9 |
| 50 | Tumor-derived CK1 \pm mutations enhance MDMX inhibition of p53. <i>Oncogene</i> , 2020, 39, 176-186. | 5.9 | 8 |
| 51 | Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. <i>Blood Advances</i> , 2022, 6, 2731-2744. | 5.2 | 8 |
| 52 | Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. <i>British Journal of Haematology</i> , 2022, 196, 617-628. | 2.5 | 7 |
| 53 | <i>PIM1</i> genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e808. | 4.0 | 7 |
| 54 | Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 816-821. | 1.3 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in SÄ©zary syndrome. <i>Leukemia and Lymphoma</i> , 2018, 59, 2405-2413. | 1.3 | 6 |
| 56 | Characteristics and outcomes of non-Hodgkinâ€™s lymphoma patients with leptomeningeal metastases. <i>International Journal of Clinical Oncology</i> , 2018, 23, 783-789. | 2.2 | 6 |
| 57 | A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma. <i>Aging</i> , 2021, 13, 22947-22962. | 3.1 | 6 |
| 58 | SET-NUP214 Fusion Gene Involved Early T-Cell Precursor Acute Lymphoblastic Leukemia in Adult with B Marker Expression. <i>International Journal of General Medicine</i> , 2021, Volume 14, 659-664. | 1.8 | 5 |
| 59 | miRâ€™150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large Bâ€™cell lymphoma. <i>Oncology Letters</i> , 2020, 19, 3487-3494. | 1.8 | 5 |
| 60 | Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7578-7578. | 1.6 | 5 |
| 61 | Identification of potential target genes associated with the effect of propranolol on angiosarcoma via microarray analysis. <i>Oncology Letters</i> , 2017, 13, 4267-4275. | 1.8 | 4 |
| 62 | Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response. <i>Journal of Drug Targeting</i> , 2020, 28, 982-990. | 4.4 | 4 |
| 63 | Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. <i>BioMed Research International</i> , 2015, 2015, 1-7. | 1.9 | 3 |
| 64 | Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia. <i>Molecular Medicine Reports</i> , 2017, 16, 281-287. | 2.4 | 3 |
| 65 | Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients. <i>Hematological Oncology</i> , 2018, 36, 779-785. | 1.7 | 3 |
| 66 | Combination of baseline total metabolic tumor volume measured on FDGâ€™PET / CT and Î²2â€™microglobulin have a robust predictive value in patients with primary breast lymphoma. <i>Hematological Oncology</i> , 2020, 38, 493-500. | 1.7 | 3 |
| 67 | An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 708784. | 2.8 | 3 |
| 68 | Bortezomib enhances the anti-cancer effect of the novel Brutonâ€™s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. <i>Aging</i> , 2021, 13, 21102-21121. | 3.1 | 3 |
| 69 | Overexpression of microRNAâ€™130a predicts adverse prognosis of primary gastrointestinal diffuse large Bâ€™cell lymphoma. <i>Oncology Letters</i> , 2020, 20, 1-1. | 1.8 | 3 |
| 70 | Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large Bâ€™cell lymphoma in the rituximab era. <i>Hematological Oncology</i> , 2021, 39, 490-497. | 1.7 | 2 |
| 71 | Baseline Characteristics of 3046 Non-Hodgkin's Lymphoma Patients Diagnosed between July 2015 and May 2018: A Report from China Lymphoma Patient Registry (CLAP). <i>Blood</i> , 2018, 132, 5394-5394. | 1.4 | 2 |
| 72 | A novel clinical immuneâ€™related prognostic model predicts the overall survival of mantle cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 343-355. | 1.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Expression of preprotachykinin-I (PPT-I), neurokinin-1 (NK-1) and neurokinin-2 (NK-2) in breast cancer cells improves tumor cell survival in bone marrow in the early stage of metastasis. <i>Clinical Oncology and Cancer Research</i> , 2009, 6, 225-232. | 0.1 | 1 |
| 74 | Identification of target gene of venous thromboembolism in patients with lymphoma via microarray analysis. <i>Oncology Letters</i> , 2017, 14, 3313-3318. | 1.8 | 1 |
| 75 | Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19507-e19507. | 1.6 | 1 |
| 76 | Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362. | 1.6 | 1 |
| 77 | Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma. <i>Journal of Cancer</i> , 2021, 12, 6126-6134. | 2.5 | 1 |
| 78 | Primary Breast Diffuse Large B Cell Lymphoma in the Rituximab Era: Outcomes of a Multicenter Retrospective Study By the Lymphoma and Leukemia Committee of Chinese Geriatric Oncology Society(LLC-CGOS). <i>Blood</i> , 2016, 128, 4228-4228. | 1.4 | 1 |
| 79 | Comprehensive analysis of <scp>TP53</scp> mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2022, 97, . | 4.1 | 1 |
| 80 | XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL): Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial). <i>Blood</i> , 2021, 138, 2452-2452. | 1.4 | 1 |
| 81 | APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3521-3521. | 1.4 | 1 |
| 82 | Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. <i>Blood</i> , 2020, 136, 17-17. | 1.4 | 1 |
| 83 | Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. <i>BioMed Research International</i> , 2022, 2022, 1-18. | 1.9 | 1 |
| 84 | Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis. <i>Hematological Oncology</i> , 2023, 41, 239-247. | 1.7 | 0 |
| 85 | Microrna-17-92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination. <i>Blood</i> , 2015, 126, 3638-3638. | 1.4 | 0 |
| 86 | Baseline Characteristics of 412 Hodgkin's Lymphoma Patients Diagnosed between July 2015 and May 2018: A Report from China Lymphoma Patient Registry (CLAP). <i>Blood</i> , 2018, 132, 5362-5362. | 1.4 | 0 |
| 87 | Pattern of Rituximab Use Among Patients with B-Cell Non-Hodgkin's Lymphoma: A Report from China Lymphoma Patient Registry (CLAP). <i>Blood</i> , 2018, 132, 5419-5419. | 1.4 | 0 |
| 88 | Efficacy and time to next treatment following lenalidomide/rituximab (R ²) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7514-7514. | 1.6 | 0 |
| 89 | Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 5231-5231. | 1.4 | 0 |
| 90 | Evaluation of the Prognostic Significance and Effect of NT5E-Adenosine Axis, a Novel Immune Checkpoint, in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2801-2801. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Comprehensive Analysis of TP53 Mutation Characteristics and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 4485-4485. | 1.4 | 0 |
| 92 | m6A Modification Patterns Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment. <i>Blood</i> , 2021, 138, 4486-4486. | 1.4 | 0 |
| 93 | Biological and Clinical Significance of PIM1 Genetic Alterations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3494-3494. | 1.4 | 0 |
| 94 | Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 17-17. | 1.4 | 0 |